Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study

Patients with estrogen receptor (ER)‐positive breast cancer are less likely to achieve a pathological complete response (pCR) with neoadjuvant chemotherapy. Neoadjuvant endocrine therapy may be more appropriate than neoadjuvant chemotherapy in these hormone‐sensitive patients. Most patients with ER‐...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Med
Hauptverfasser: Sato, Nobuaki, Masuda, Norikazu, Morimoto, Takashi, Ueno, Takayuki, Kanbayashi, Chizuko, Kaneko, Koji, Yasojima, Hiroyuki, Saji, Shigehira, Sasano, Hironobu, Morita, Satoshi, Ohno, Shinji, Toi, Masakazu
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2018
Schlagworte:
Clinical Cancer Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6051169/
https://ncbi.nlm.nih.gov/pubmed/29905023
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1600
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge